Back to List View Graph View

RAS

RAS refers to a family of small, membrane-associated guanosine triphosphatases (GTPases) that function as molecular switches in intracellular signal transduction.

Where the papers sit

12 papers from the last 6 months study RAS directly · updated from PubMed 10 Nov 2026

  • KRAS-Driven Pancreatic Cancer

    KRAS and related RAS mutations anchor efforts to prevent or treat pancreatic cancer. Interception strategies aim to act before invasive disease, while daraxonrasib is being tested with chemotherapy in previously treated metastatic disease. Molecular profiling and TNM staging seek better prognostic stratification, with tumor mutational burden adding context. The main open question is whether RAS inhibition can improve outcomes beyond current chemotherapy.

    4 papers · 33.3%

  • Cancer Surgery Outcomes

    Clinical management is being compared through survival, complications, operating time and resource use across gastrointestinal and gynecologic cancers. Robotic and laparoscopic surgery are assessed for endometrial and rectal cancer, while thermal ablation offers local control for multisite colon metastases. In metastatic colorectal cancer, systemic inflammation is being evaluated alongside anti-EGFR treatment as a prognostic factor. Evidence remains heterogeneous, combining outcome analyses with prospective health-technology assessment.

    4 papers · 33.3%

  • RAS/MAPK Targeted Therapy

    RAS/MAPK blockade is moving toward selective inhibitors paired with biomarker-defined vulnerabilities rather than single-pathway suppression. RAS(ON) multiselective inhibitors are being evaluated in NRAS-mutated melanoma and KRAS-driven disease, while KRAS G12C and MEK inhibition remain central therapeutic contexts. Multiomic analysis of microsatellite-stable colorectal cancer and FAK-related signaling seeks combinations that widen the therapeutic index. Resistance mechanisms and combination durability remain unresolved.

    4 papers · 33.3%

Papers

The 12 papers from the last 6 months that study RAS directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

KRAS-Driven Pancreatic Cancer (4)
  1. Targeting RAS for Pancreatic Cancer Interception. Cancer discovery · 22 Sept 2026 PMID 42770704
  2. Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations. Endocrine pathology · 12 Sept 2026 PMID 42730891
  3. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
  4. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223072
Cancer Surgery Outcomes (4)
  1. Robotic-assisted versus laparoscopic hysterectomy in Stage I endometrial cancer: a real-world causal mediation analysis of operating time and length of hospital stay. Journal of robotic surgery · 3 Nov 2026 PMID 42975740
  2. Multidisciplinary Treatment With Repeated Thermal Ablation for Multisite Metastatic Colon Cancer in an Elderly Patient. Anticancer research · 1 Oct 2026 PMID 42823149
  3. Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
  4. Health technology assessment of robotic surgery for rectal cancer in China: protocol for a nationally multicentre prospective cohort study. BMJ open · 17 Sept 2026 PMID 42754273
RAS/MAPK Targeted Therapy (4)
  1. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896
  2. Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities. Cancer cell · 23 Oct 2026 PMID 42913633
  3. MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers. Cancer research · 15 Oct 2026 PMID 42876249
  4. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. Cancer research · 22 May 2026 PMID 42171647

By study type

Clinical trials (1)
  1. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223072
Observational studies and case reports (5)
  1. Robotic-assisted versus laparoscopic hysterectomy in Stage I endometrial cancer: a real-world causal mediation analysis of operating time and length of hospital stay. Journal of robotic surgery · 3 Nov 2026 PMID 42975740
  2. Multidisciplinary Treatment With Repeated Thermal Ablation for Multisite Metastatic Colon Cancer in an Elderly Patient. Anticancer research · 1 Oct 2026 PMID 42823149
  3. Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
  4. Health technology assessment of robotic surgery for rectal cancer in China: protocol for a nationally multicentre prospective cohort study. BMJ open · 17 Sept 2026 PMID 42754273
  5. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
Human data, design not indexed (1)
  1. Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations. Endocrine pathology · 12 Sept 2026 PMID 42730891
Preclinical: animal, cell and lab studies (4)
  1. Multiomic characterization of microsatellite-stable colorectal cancer reveals distinct biology and targetable vulnerabilities. Cancer cell · 23 Oct 2026 PMID 42913633
  2. MEKing Room: On the Quest for New Sources of Therapeutic Index in RAS/MAPK-Driven Cancers. Cancer research · 15 Oct 2026 PMID 42876249
  3. Targeting RAS for Pancreatic Cancer Interception. Cancer discovery · 22 Sept 2026 PMID 42770704
  4. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. Cancer research · 22 May 2026 PMID 42171647
Unclassified: not yet indexed with MeSH (1)
  1. Rat sarcoma inhibitors in and beyond gynecologic malignancies. Current opinion in obstetrics & gynecology · 24 Oct 2026 PMID 42924896